Wagh, IN
Balasaheb Parshuram Wagh, Maharashtra IN
Patent application number | Description | Published |
---|---|---|
20150250734 | Stable pharmaceutical compositions of saxagliptin or salts thereof - The present invention refers to a stable pharmaceutical composition of saxagliptin or salts thereof. In particular, the invention relates to stable comprises a core and two or more layers coated on the core, wherein the composition or the inner first coat is free of polyvinyl alcohol. Such composition of saxagliptin may exhibit relatively improved storage stability and particularly, levels of degradants in the formulation during storage can be effectively controlled. The invention also includes a process of preparing such compositions and method of treating type-II diabetes mellitus by administering the composition to a patient in need thereof. | 09-10-2015 |
Ganesh Wagh, Mumbai IN
Patent application number | Description | Published |
---|---|---|
20080200732 | Novel Intermediates Useful for the Preparation of Coenzymes, Process for the Preparation of Novel Intermediates and an Improved Process for the Preparation of Coenzymes - The present invention relates to novel intermediates for the preparation of coenzymes, processes for the preparation of the intermediates and an improved process for the preparation of Coenzymes. The present invention particularly relates to an improved process for the preparation of Coenzyme Q, more particularly for Conenzyme Q | 08-21-2008 |
20150252001 | PROCESS FOR PREPARATION OF PERINDOPRIL INTERMEDIATE - The present invention relates to an improved process for the preparation Of (2S,3aS,7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]3-S-oxopropyl]octahydro-1H-indole-2-carboxylic acid benzyl ester (the compound of formula II) comprising reacting (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid phenylmethyl ester | 09-10-2015 |
20160031867 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT - The present invention provides a process for the preparation of 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-one (Aprepitant) comprising condensation of 2-(R)-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(S)-(4-fluorophenyl)morpholine hydrochloride salt with 2-(2-chloro-1-iminoethyl)hydrazinecarboxylic acid methyl ester to obtain the reaction mixture containing 2-[2-[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]-1-iminoethyl]hydrazinecarboxylic acid methyl ester, which is in-situ cyclized in the presence of dimethylsulfoxide and a polar protic solvent at a low temperature to yield aprepitant having purity ≧99.5%. | 02-04-2016 |
Ganesh Wagh, Maharashtra IN
Patent application number | Description | Published |
---|---|---|
20080200733 | Processes For The Preparation Of Purified Solanesol, Solanesyl Bromide & Solanesyl Acetone - The present invention relates to processes for the preparation of purified solanesol, solanesyl bromide & solanesyl acetone. Solanesyl acetone has the chemical name—all—trans 6,10,14,18,22,26,30,34,38-nonamethyl-5,9,13,17,21,25,29,33,37-triacontanonaen-2-one, of formula 1 and is used for synthesis of coenzyme Q | 08-21-2008 |
Manoj Balu Wagh, Nashik IN
Patent application number | Description | Published |
---|---|---|
20130172562 | PROCESS FOR THE PREPARATION OF A SINGLE ENANTIOMER OF 3-AMINOPIPERIDINE DIHYDROCHLORIDE - A process comprising: (a) reduction of N-acetyl-3-aminopyridine (2): or its salt in the presence of hydrogen and a palladium catalyst deposited on solid support; (b) converting racemic N-acetyl-3-aminopiperidine (3) or its salt produced in step (a) to rac-3-aminopiperidine (rac-4) or its salt; (c) resolution of the racemic 3-aminopiperidine (rac-4) or its salt produced in step (b) with a chiral acid. | 07-04-2013 |
Nilesh Wagh, Nasik IN
Patent application number | Description | Published |
---|---|---|
20110263543 | ANTI INFLAMMATORY COMPOUNDS - Biphenyl compounds of Formula (I) and Formula (II), and their pharmaceutically acceptable salts or solvates or prodrugs, their pharmaceutical compositions, their use and process of preparation are provided. Compounds of Formula (I) and Formula (II) are disclosed to exhibit anti-inflammatory properties. | 10-27-2011 |
Pradip Balu Wagh, Nashik IN
Patent application number | Description | Published |
---|---|---|
20140155398 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS - The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R | 06-05-2014 |
20150157613 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS - The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R | 06-11-2015 |
Sachin Ashok Wagh, Mumbai IN
Patent application number | Description | Published |
---|---|---|
20100017514 | Method for determining service demands in a network load balanced scenario - An approach to determine the service demand of various resources of any individual server (present in a cluster of servers), given the overall transaction throughput and utilization values of these resources, in case of a network load balanced scenario is disclosed. The method proposes a quantitative approach to calculate the transaction throughput of each network load balanced server from the overall transaction throughput, obtained from any commercial performance testing tool. The individual transaction throughputs are calculated using monitored values of network related performance counters of each server and the load balancer obtained from performance testing. Service demands of the resource can be computed using the Utilization law of Queuing Theory once the throughput of that server and utilization of that resource is obtained. | 01-21-2010 |
Sachin Bhausaheb Wagh, Pune, Maharashtra IN
Patent application number | Description | Published |
---|---|---|
20160115181 | NOVEL PYRROLE COMPOUNDS WITH SILICON INCORPORATION - The present invention discloses novel Silicon incorporated pyrrole compounds of Formula I having potential anti-bacterial properties. The invention further discloses a process for synthesis of pyrrole compounds with silicon incorporation of Formula I and to the pharmaceutical composition thereof. | 04-28-2016 |
Sanjay Wagh, Pune IN
Patent application number | Description | Published |
---|---|---|
20140171401 | NOVEL PHARMACEUTICAL FORMULATION OF CEFIXIME FOR ENHANCED BIOAVAILABILITY - A chewable tablet comprising Cefixime having a mean particle size between 20μ and 120μ wherein the said composition demonstrates bioequivalence to a suspension of Cefixime trihydrate. The process of preparation of the chewable tablet comprises the steps of optionally micronizing Cefixime such that the mean particle size of the Cefixime particles is between 20μ and 120μ, blending with other excipients, roll compaction, milling to form granules, blending to form a secondary blend and compression of the secondary blend to form tablets. | 06-19-2014 |
Sanjay Chhagan Wagh, Maharashtra IN
Patent application number | Description | Published |
---|---|---|
20090022809 | STABLE TASTE MASKED FORMULATIONS OF CEPHALOSPORINS - A stable taste masked, pharmaceutical composition comprising a plurality of coated, non-disintegrating discrete dosage units, said units comprising of a core comprising one or more cephalosporins such as cefuroxime axetil and cefpodoxime proxetil and one or more coating layers. Cefuroxime axetil is in α-crystalline and amorphous forms, where at least 30% of the Cefuroxime axetil is in the α-crystalline form, wherein the particle size distribution of the α-crystalline form being such that 100% of the particles have a particle size below 250μ. The ratio of the crystalline fraction to the amorphous fraction ranges from 0.3:0.7 to 0.99:0.01. The particle size of cefpodoxime proxetil is such that 90% of the particles are below 15μ. The process of preparation of coated, non-disintegrating pellets comprising the steps of reducing the particle size of the one or more cephalosporins, blending with the other excipients, wet granulation, extrusion, spheronization, drying and screening to obtain pellets, said pellets being further coated with one or more layers of film coating to achieve taste masking. | 01-22-2009 |
20090197855 | PHARMACEUTICAL COMPOSITIONS OF CEFDINIR - A chewable tablet dosage form comprising Cefdinir or pharmaceutically acceptable salts thereof for the oral administration of Cefdinir in a manner that is more palatable and less objectionable to population group's especially young children and older patients. A method of preparing the chewable tablets comprising Cefdinir and method of treatment using the same. | 08-06-2009 |
20100009955 | PHARMACEUTICAL COMPOSITIONS OF CEFIXIME - A pharmaceutical suspension formulation comprising a dose greater than 100 mg/5 ml Cefixime and pharmaceutically acceptable excipients. | 01-14-2010 |
Sanjay Chhagan Wagh, Nashik IN
Patent application number | Description | Published |
---|---|---|
20100260842 | PSEUDOEPHEDRINE PHARMACEUTICAL FORMULATIONS - Controlled-release pharmaceutical formulations comprising pseudoephedrine or any of its pharmaceutically acceptable salts, processes for preparing the pharmaceutical formulations, and methods of using the formulations. | 10-14-2010 |
Sanjay Chhagan Wagh, Hyderabad IN
Patent application number | Description | Published |
---|---|---|
20110009362 | SOLUBILITY-ENHANCED FORMS OF APREPITANT AND PHARMACEUTICAL COMPOSITIONS THEREOF - Solubility-enhanced forms of aprepitant and processes for preparing such forms. The invention also provides solubility-enhanced forms of aprepitant that also possess stability against solid state conversions. Certain solubility-enhanced forms of aprepitant comprise a cyclodextrin or any of its derivatives. Other solubility-enhanced forms of aprepitant comprise fine particle preparations of aprepitant. The invention further provides non-nanoparticulate pharmaceutical formulations prepared using solubility-enhanced forms of aprepitant. The invention also provides taste-masked and orally disintegrating pharmaceutical formulations comprising aprepitant. Further, pharmaceutical formulations comprising solubilityenhanced forms of aprepitant and processes of preparation of such formulations, as well as methods of using them are provided. | 01-13-2011 |
20110064816 | ATORVASTATIN COMPOSITIONS - Compositions containing atorvastatin, including its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs and their mixtures, and processes for preparing the same. Further aspects relate to pharmaceutical formulations comprising compositions containing atorvastatin, or a salt thereof, processes for preparing the same, and their methods of use, treatment and administration. | 03-17-2011 |
Snehal Madhavrao Wagh, Pune IN
Patent application number | Description | Published |
---|---|---|
20100212376 | Locking System for a Storage Container - A lock system for a tool box is disclosed wherein locking is achieved with a lock which is located in a recessed portion along the front wall of the tool box in order to prevent tampering. A latch rod is slidably disposed adjacent a front wall of the box. The lock and the latch rod are disposed such that the lock body blocks the longitudinal movement of a lock engager and maintains the latch rod in the latched position when the lid of the tool box is in the closed position and the lock is locked. When the lock is unlocked, the lock engager is allowed to move past the lock to move the latch rod to the unlatched position thereby allowing the lid of the tool box to be opened. The lock system may be used for a horizontal or a vertical tool box. | 08-26-2010 |
Vilas Wagh, Mumbai IN
Patent application number | Description | Published |
---|---|---|
20100028472 | HERBAL COMPOSITION AND PROCESS FOR ITS PREPARATION - A herbal composition comprising a therapeutically effective amount of the extract of | 02-04-2010 |
Vilas Sampatrao Wagh, Mumbai IN
Patent application number | Description | Published |
---|---|---|
20100010002 | ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES - The present invention relates to the use of caffeic acid or a derivative thereof represented by the following general formula (1) | 01-14-2010 |